📰 Offer Booklet News
Offer Booklet News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Offer Booklet. Real-time updates on events, politics, business and more.
March 13, 2023
Global semiconductor developer BluGlass Limited has secured $10.2 million in commitments from international and Australian institutional and sophisticated investors via a strongly supported share placement at an issue price of $0.06 per share.
December 29, 2022
Perth, Western Australia--(Newsfile Corp. - December 29, 2022) - The Board of Besra Gold Inc (ASX: BEZ) refers to its fully underwritten non-renounceable entitlement offer of one new CDI (New CDIs) for
November 4, 2022
Investegate announcements from MC Mining Limited, Fully Underwritten Rights Issue Offer Closes
September 27, 2022
Investegate announcements from MC Mining Limited, Fully Underwritten A$40M Rights Issue
June 30, 2022
Empire Energy Group Limited (ASX:EEG) (OTCMKTS:EEGUF) is pleased to announce that the Companys Share Purchase Plan to raise $2.5 million has been fully underwritten by Blue Ocean Equities Pty Limited.
December 3, 2021
For personal use only Offer Booklet Non-renounceable entitlement offer of 1 new share for every 1... | December 2, 2021
December 13, 2020
Musgrave Minerals Ltd (ASX:MGV) $18M Raising to Fund Resource Growth and Company Presentation $18M Raising to Fund Resource Growth and Company PresentationPerth, Dec 14, 2020 AEST (ABN Newswire) - Musgrave Minerals Limited ( FRA:6MU) is pleased to advise that it has received firm commitments to raise $16 million (before costs) via a placement of 44,444,445 shares (New Shares) at an issue price of $0.36 per New Share to corporate, institutional, professional and sophisticated investors (...
December 11, 2020
, 3. Key preparation activities are now underway to advance clinical programs in these high priority target indications including (but not limited to): trial design, regulatory consultation, endpoint selection, key opinion leader engagements and clinical site selection. The Company will continue to develop its existing clinical product pipeline in addition to these new targets and will continue to drive its partnering strategy. Further background information on the new target indications is pro...